Novel transcript, antisense to ERBB2

The "novel transcript, antisense to ERBB2" is a non-coding RNA transcribed in the opposite orientation to the ERBB2 (HER2) gene. Such antisense transcripts, known as natural antisense transcripts (NATs), can regulate the expression of their sense counterparts through mechanisms like chromatin modification, recruitment of repressive complexes, or by affecting transcriptional machinery[3]. While antisense regulation is a growing area in functional genomics, there is currently limited characterization or evidence that this specific transcript is a validated therapeutic target or biomarker, nor is there information about its aliases or exact functional details. Typically, proteins (like the ERBB2 tyrosine kinase itself[5][1]) are the established therapeutic targets, whereas antisense RNAs are less commonly directly targeted in approved therapeutics. This target is labeled **is_incorrect: true** because: - It is not a canonical therapeutic target (not an enzyme, receptor, transporter, etc.) - There is insufficient public information or consensus about its nomenclature, function, or relevance as a drug target - The entry appears to refer generically to an uncharacterized transcript, rather than an established molecular entity If you are seeking a canonical target related to ERBB2/HER2, it would be "Erb-B2 receptor tyrosine kinase 2" (HER2), which is a well-established receptor and therapeutic target in cancer[5][1]. The "novel transcript, antisense to ERBB2" is not equivalent to HER2 or ERBB2 and should not be used as a canonical target in drug discovery or clinical informatics.

Other names

Antisense ERBB2 transcriptNatural antisense transcript to ERBB2ERBB2-AS (speculative, not established)

Not applicable; not a direct druggable protein, but inhibition of analogous antisense transcripts can upregulate corresponding sense gene expression in other cases[3]